Recent developments in research
- Research summary: resistance to sevabertinib in HER2+ NSCLC
- 18-month update: targeting mSWI/SNF in KRAS+ lung cancer
- CROWN Trial: 7-year update
- Work presented at ASCO meeting could impact lung cancer treatment
- CAR T-cell therapy for lung cancer
- LCRF | Boehringer Ingelheim Team Science Award on understanding and treating HER2+ lung cancers
Science Made Simple
- Sevabertinib for HER2+ lung cancer
- Zidesamtinib for ROS1+ NSCLC
- CROWN Trial: 7-year update
- Work presented at ASCO meeting could impact lung cancer treatment
- CAR T-cell therapy for lung cancer
- Zongertinib approved as first-line HER2+ lung cancer treatment
- AI for Lung Cancer Screening
- Lung cancer in 2025
- Subcutaneous amivantamab